Edition:
India

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

13.98USD
27 Mar 2020
Change (% chg)

$-0.46 (-3.19%)
Prev Close
$14.44
Open
$13.90
Day's High
$14.52
Day's Low
$13.44
Volume
300,889
Avg. Vol
423,575
52-wk High
$37.00
52-wk Low
$10.09

Latest Key Developments (Source: Significant Developments)

FDA Approves Aimmune's Palforzia As First Treatment For Peanut Allergy
Saturday, 1 Feb 2020 

Jan 31 (Reuters) - Aimmune Therapeutics Inc ::FDA APPROVES AIMMUNE’S PALFORZIA™ AS FIRST TREATMENT FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS INC - PRESCRIBING INFORMATION FOR PALFORZIA CONTAINS A BOXED WARNING.  Full Article

Aimmune Therapeutics Reports Third Quarter Results
Thursday, 7 Nov 2019 

Nov 6 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES OPERATIONAL HIGHLIGHTS.AIMMUNE THERAPEUTICS INC - CASH, CASH EQUIVALENTS, & INVESTMENTS TOTALED $200.5 MILLION ON SEPTEMBER 30, 2019.AIMMUNE THERAPEUTICS INC QTRLY LOSS PER SHARE $1.03.AIMMUNE THERAPEUTICS INC - EXPECT FDA REVIEW ACTION DATE FOR PALFORZIA BLA IN JANUARY 2020.  Full Article

Aimmune Therapeutics Qtrly Loss Per Share $1.01
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES OPERATIONAL HIGHLIGHTS.AIMMUNE THERAPEUTICS INC QTRLY LOSS PER SHARE $1.01.AIMMUNE THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND INVESTMENTS TOTALED $250.3 MILLION ON JUNE 30, 2019, COMPARED TO $303.9 MILLION ON DECEMBER 31, 2018.  Full Article

European Phase 3 Trial Of Aimmune Therapeutics' AR101 Meets Primary Endpoint
Monday, 25 Mar 2019 

March 25 (Reuters) - Aimmune Therapeutics Inc ::EUROPEAN PHASE 3 TRIAL OF AIMMUNE THERAPEUTICS’ AR101 MEETS PRIMARY ENDPOINT.AIMMUNE THERAPEUTICS INC - INTENDS TO SUBMIT EUROPEAN MAA IN MID-2019.AIMMUNE THERAPEUTICS INC - SAFETY PROFILE AND COMPLETION RATE OBSERVED IN ARTEMIS ARE CONSISTENT WITH RESULTS SEEN IN PREVIOUS AR101 CLINICAL TRIALS.AIMMUNE THERAPEUTICS INC - NO CASES OF ANAPHYLAXIS OR OF EOSINOPHILIC ESOPHAGITIS (EOE) WERE OBSERVED.AIMMUNE THERAPEUTICS - PLANS TO PRESENT FULL RESULTS IN ORAL PRESENTATION AT EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY CONGRESS IN EARLY JUNE.  Full Article

Aimmune Therapeutics Announces Fourth Quarter Results
Friday, 1 Mar 2019 

Feb 28 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES RECENT OPERATIONAL HIGHLIGHTS.Q4 LOSS PER SHARE $0.95.CASH, CASH EQUIVALENTS, & INVESTMENTS TOTALED $303.9 MILLION ON DEC 31, 2018, COMPARED TO $182.4 MILLION ON DEC 31, 2017.  Full Article

Aimmune Therapeutics Submits BLA To FDA For Ar101 For The Treatment Of Peanut Allergy In Children And Adolescents Ages 4–17
Saturday, 22 Dec 2018 

Dec 21 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS SUBMITS BLA TO FDA FOR AR101 FOR THE TREATMENT OF PEANUT ALLERGY IN CHILDREN AND ADOLESCENTS AGES 4–17.  Full Article

Nestle Health Science Us Holdings Inc Reports 18.9 Percent Stake In Aimmune Therapeutics As Of Nov 28
Tuesday, 4 Dec 2018 

Dec 3 (Reuters) - :NESTLE HEALTH SCIENCE US HOLDINGS, INC REPORTS 18.9 PERCENT STAKE IN AIMMUNE THERAPEUTICS INC AS OF NOV 28, 2018 - SEC FILING.NESTLE HEALTH SCIENCE US HOLDINGS, INC - HAD PREVIOSULY REPORTED 15.0 PERCENT STAKE IN AIMMUNE THERAPEUTICS INC AS OF FEB 26, 2018.  Full Article

Aimmune Therapeutics Qtrly Loss Per Share $0.89
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.AIMMUNE THERAPEUTICS INC - AS OF SEPTEMBER 30, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $255.2 MILLION.AIMMUNE THERAPEUTICS INC QTRLY LOSS PER SHARE $0.89.  Full Article

Aimmune Therapeutics Reports Q1 Loss Per Share $0.92
Wednesday, 9 May 2018 

May 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.92.Q1 EARNINGS PER SHARE VIEW $-0.71 -- THOMSON REUTERS I/B/E/S.  Full Article

Aimmune sees coronavirus slowing down marketing of peanut allergy therapy

Aimmune Therapeutics Inc on Monday warned of a slow launch of its peanut allergy therapy, as its marketing plans take a hit from U.S. authorities' recommendation of social distancing to contain the spread of the coronavirus.